Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Des C Jones

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Transplantation|October 5, 2002
Genetic determinants of delayed graft function after kidney transplantationShawn D St Peter, Charles J Imber, Des C Jones, et al.
Oncotarget|January 16, 2016
Allele-specific recognition by LILRB3 and LILRA6 of a cytokeratin 8-associated ligand on necrotic glandular epithelial cellsDes C Jones, Colin R A Hewitt, María R López-Álvarez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 29, 2011
HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor bindingDes C Jones, Vasilis Kosmoliaptsis, Richard Apps, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2015
TARM1 Is a Novel Leukocyte Receptor Complex-Encoded ITAM Receptor That Costimulates Proinflammatory Cytokine Secretion by Macrophages and NeutrophilsValeria Radjabova, Piero Mastroeni, Karsten Skjødt, et al.
Scientific Reports|November 27, 2025
Characterisation of human in vitro tumour-associated macrophage models to define translational relevanceArthur Dyer, Rebecca Dudley, Shreya Ahuja, et al.
Cancer Immunology Research|December 23, 2021
Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1Madhu Ramaswamy, Taeil Kim, Des C Jones, et al.
JCI Insight|September 2, 2020
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulationMuchaala Yeboah, Charys Papagregoriou, Des C Jones, et al.
Journal for Immunotherapy of Cancer|April 17, 2025
LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunityDes C Jones, Lorraine Irving, Rebecca Dudley, et al.
Plos Genetics|March 8, 2014
LILRB2 interaction with HLA class I correlates with control of HIV-1 infectionArman A Bashirova, Enrique Martin-Gayo, Des C Jones, et al.
Cancer Discovery|January 9, 2021
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T CellsSimon J Dovedi, Matthew J Elder, Chunning Yang, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Transplantation|October 5, 2002
Genetic determinants of delayed graft function after kidney transplantationShawn D St Peter, Charles J Imber, Des C Jones, et al.
Oncotarget|January 16, 2016
Allele-specific recognition by LILRB3 and LILRA6 of a cytokeratin 8-associated ligand on necrotic glandular epithelial cellsDes C Jones, Colin R A Hewitt, María R López-Álvarez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 29, 2011
HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor bindingDes C Jones, Vasilis Kosmoliaptsis, Richard Apps, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2015
TARM1 Is a Novel Leukocyte Receptor Complex-Encoded ITAM Receptor That Costimulates Proinflammatory Cytokine Secretion by Macrophages and NeutrophilsValeria Radjabova, Piero Mastroeni, Karsten Skjødt, et al.
Scientific Reports|November 27, 2025
Characterisation of human in vitro tumour-associated macrophage models to define translational relevanceArthur Dyer, Rebecca Dudley, Shreya Ahuja, et al.
Cancer Immunology Research|December 23, 2021
Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1Madhu Ramaswamy, Taeil Kim, Des C Jones, et al.
JCI Insight|September 2, 2020
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulationMuchaala Yeboah, Charys Papagregoriou, Des C Jones, et al.
Journal for Immunotherapy of Cancer|April 17, 2025
LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunityDes C Jones, Lorraine Irving, Rebecca Dudley, et al.
Plos Genetics|March 8, 2014
LILRB2 interaction with HLA class I correlates with control of HIV-1 infectionArman A Bashirova, Enrique Martin-Gayo, Des C Jones, et al.
Cancer Discovery|January 9, 2021
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T CellsSimon J Dovedi, Matthew J Elder, Chunning Yang, et al.
Pageof 2